Sarepta Therapeutics
Sarepta develops and commercializes ribonucleic acid targeted therapeutics for the treatment of neuromuscular diseases.
Business Model:
Revenue: $876M
Employees: 501-1,000
Industries / Tags:
Detailed Sarepta Therapeutics Information
Geographic Data
Address: 215 First Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$500M
Raised Total:$1B
Social
Metrics
1,444,299Website Global Rank
18,464Website Monthly Traffic
Twitter Followers
Description
Sarepta develops and commercializes ribonucleic acid targeted therapeutics for the treatment of neuromuscular diseases.
Contact Phone:
+16172744000
Contact Email:
Sarepta Therapeutics went public on 6/4/1997 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/4/1997
IPO Valuation:
$96M
Ticker Symbol:
SRPT
IPO Price:
$9/share
Amount Raised:
$18M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2018 | Myonexus Therapeutics | Corporate Round | 60M |
| 8/2018 | Lacerta Therapeutics | Equity | 30M |
| 10/2020 | AavantiBio | Series A | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 10/2020 | AavantiBio | Series A | 0 |
| 8/2018 | Lacerta Therapeutics | Venture Round | 0 |
| 5/2018 | Myonexus Therapeutics | Corporate Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2017 | Post-IPO Debt | 1 | $100M |
MidCap Financial MidCap Financial MidCap Financial MidCap Financial |
10/2018 | Post-IPO Equity | $90M | 2/2020 | Post-IPO Equity | $0 |
Roche Financial Roche Financial |
6/2015 | Post-IPO Debt | $40M | 11/2019 | Post-IPO Equity | $30.5M | 9/2022 | Post-IPO Equity | 1 | $6M |
Michael Andrew Chambers Michael Andrew Chambers |
7/2017 | Post-IPO Debt | $60M |
MidCap Financial |
9/2022 | Post-IPO Debt | $979.4M | 12/2019 | Post-IPO Debt | 1 | $250M |
Pharmakon Advisors Pharmakon Advisors Pharmakon Advisors Pharmakon Advisors |
10/2021 | Post-IPO Equity | $500M | 2/2020 | Post-IPO Equity | 1 | $400M |
Roche Financial |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 2/2019 | Myonexus Therapeutics | |
| 7/2014 | Eisai | |
| 3/2008 | Ercole Biotech |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
